Bank of Nova Scotia
EBS icon

Bank of Nova Scotia’s Emergent Biosolutions EBS Stock Holding History

Bank of Nova Scotia’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-7,200
Closed -$291K – 930
2017
Q3 		$291K Buy
+7,200
New +$261K ﹤0.01% 879

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of Nova Scotia's EBS Position: Q4 2017 in Review

Bank of Nova Scotia sold out of Emergent Biosolutions (EBS) in Q4 2017, closing a stake of 7,200 shares — an estimated $291K sold.

Bank of Nova Scotia first reported a position in EBS in Q3 2017 and held it in 1 quarter. The position peaked at $291K in Q3 2017. 238 funds tracked by Wall St. Rank hold EBS as of Q4 2017.

  • Bank of Nova Scotia reported no remaining Emergent Biosolutions position as of Q4 2017 after selling out during the quarter.
  • Bank of Nova Scotia sold 7,200 Emergent Biosolutions shares in Q4 2017, an estimated $291K.
  • Bank of Nova Scotia first reported a position in Emergent Biosolutions in Q3 2017 and held it in 1 quarter.
  • Bank of Nova Scotia's Emergent Biosolutions position peaked at $291K in Q3 2017.
  • 238 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2017.

Based on Bank of Nova Scotia's 13F filing for Q4 2017, filed 14 Feb 2018.